There's no bigger or broader a health care firm on the markets than Johnson & Johnson (NYSE:JNJ). This medical giant sells everything from orthopedic devices to bandages, but it's J&J's top-of-the-line pharmaceuticals that get Wall Street really excited. No other industry has the power to delight -- or disappoint -- like the pharmaceutical industry, and for Johnson & Johnson's drug business, it's done more of the former over the past.
With the patent cliff hitting sales across the industry, however, let's take a look ahead. Which of J&J's drugs have the most promise for the future, and which will investors across health care be talking about for years to come? In the video below, Motley Fool contributor Dan Carroll takes you through three of J&J's most exciting young and developing pharmaceuticals -- and what you can expect from these blossoming stars.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Dividend Stocks That Pay Out Over $8 Billion a Year
Can these huge companies keep the big dividend bucks flowing?
Johnson & Johnson Aims to Start 2018 Healthy
Investors have high hopes for the healthcare conglomerate.
Is Johnson & Johnson a Buy?
Is now a good time to invest in the healthcare titan's stock?